Axis – Dec 16, 2020
According to new research published in the December issue of The Journal of Nuclear medicine, the Imaging agent 64Cu-CuSarTate produced high-quality PET images in a mouse model of neuroendocrine tumors, while its therapeutic counterpart, 67Cu-CuSarTate, was highly effective in reducing tumor volume and extending lifespan.
Treatment of tumors with two fractions of either 177Lu-LuTATE or 67Cu-CuSarTate significantly improved survival when compared to delivery as a single fraction. Equivalent efficacy was observed between the two therapies following treatment on both the single and fractionated schedules.
Rodney J. Hicks, MBBS, MD, FRACP, FAHMS, professor in the Sir Peter MacCallum in Melbourne and Paul S. Donnelly, BSc(Hons), PhD, professor at the University of Melbourne comment the study.